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Background: It has been recently recognized that the descending serotonin (5-HT) system from the rostral
ventromedial medulla (RVM) in the brainstem and the 5-HT3 receptor subtype in the spinal dorsal horn are involved
in enhanced descending pain facilitation after tissue and nerve injury. However, the mechanisms underlying the
activation of the 5-HT3 receptor and its contribution to facilitation of pain remain unclear.
Results: In the present study, activation of spinal 5-HT3 receptors by intrathecal injection of a selective 5-HT3
receptor agonist SR 57227 induced spinal glial hyperactivity, neuronal hyperexcitability and pain hypersensitivity in
rats. We found that there was neuron-to-microglia signaling via the chemokine fractalkine, microglia to astrocyte
signaling via cytokine IL-18, astrocyte to neuronal signaling by IL-1β, and enhanced activation of NMDA receptors in
the spinal dorsal horn. Glial hyperactivation in spinal dorsal horn after hindpaw inflammation was also attenuated
by molecular depletion of the descending 5-HT system by intra-RVM Tph-2 shRNA interference.
Conclusions: These findings offer new insights into the cellular and molecular mechanisms at the spinal level
responsible for descending 5-HT-mediated pain facilitation during the development of persistent pain after tissue
and nerve injury. New pain therapies should focus on prime targets of descending facilitation-induced glial
involvement, and in particular the blocking of intercellular signaling transduction between neurons and glia.
Keywords: 5-HT3 receptor, Glia, Proinflammatory cytokines, NMDA receptor, PainBackground
Recent studies indicate that behavioral hypersensitivity
and neuronal hyperexcitability in the CNS in animal
models of persistent pain are closely linked to long-lasting
activation of descending modulatory circuits involving
descending facilitation ([1-5] See [6-10] for reviews). It has
been well established that the descending serotonin (5-
HT) system from the rostral ventromedial medulla (RVM)
of the brainstem is involved in the modulation of spinal
nociceptive transmission [11-14]. Selective lesions of
spinal 5-HT fibers [15] or molecular depletion of 5-HT in* Correspondence: fwei@umaryland.edu
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unless otherwise stated.RVM neurons [16] have been reported to attenuate behav-
ioral hypersensitivity following injury. These effects of the
descending 5-HT system resulted from the activation of
diverse 5-HT receptor subtypes found in the spinal dorsal
horn [17-19]. 5-HT3 receptors, the only ligand-gated cat-
ion channel with excitatory functions in the 5-HT recep-
tor family, are expressed in spinal dorsal horn neurons
and the central terminals of primary afferent neurons
[20,21]. Spinal 5-HT3 receptor-dependent descending pain
facilitation has recently been implicated in the develop-
ment of inflammatory and neuropathic pain [5,19,22-25].
However, the signaling cascade underlying the contribu-
tion of spinal 5-HT3 receptors to descending pain facilita-
tion remains unclear.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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contribute to pain hypersensitivity after injury [26-30]. In
addition to glutamate, spinal neurons and the central ter-
minals of primary afferents release chemokines, such as
fractalkine (CX3CL1), activating nearby glial cells [31,32].
Furthermore, hyperactivated glia amplify neuronal excit-
ability and facilitate nociceptive transmission in spinal cord
via release of pro-inflammatory cytokines (e.g. IL-1β and
TNF-α) [33-35]. Increasing attention has been given to
neuron-glia-neuron signaling as a driving force in the de-
velopment and maintenance of persistent pain [26-30].
Utilizing a model of 5-HT3 receptor agonist-induced
hyperalgesia, we tested the hypothesis that neuron-glial in-
teractions involving chemokine/cytokine signaling mole-
cules underlie mechanisms of pain hypersensitivity after
spinal 5-HT3 receptor activation. Our findings provide
evidence that a spinal neuron-glia-neuron signaling cas-
cade including endogenous fractalkine, the cytokines
IL-18 and IL-1β, and neuronal GluN (NMDA) receptor
activation, contribute to 5-HT3 receptor-mediated hyper-
algesia. Thus, spinal neuron-glial interactions underlying
the development of hyperalgesia and allodynia not only
depend on nociceptive drive from primary afferents after
tissue and nerve injury [35,36], but also require main-
tenance of descending facilitation from RVM 5-HT-spinal
5-HT3 receptor systems.
Results
Activation of spinal 5-HT3 receptors induces hyperalgesia
and allodynia
Our previous study demonstrated that descending 5-HT-
dependent pain facilitation contributes to behavioral
hyperalgesia and allodynia after peripheral inflammation
and nerve injury [16,37,25]. Recently, we also found that
the spinal 5-HT3 receptor mediated the development of
pain hypersensitivity after inflammation induced by hind-
paw injection of complete Freund’s adjuvant (CFA) [24]
and maintained persistent pain states after trigeminal
nerve injury [25,37]. To further confirm an involvement of
the spinal 5-HT3 receptor in persistent pain, we examined
the effect of the blockade of spinal 5-HT3 receptor func-
tion on the maintenance of pain hypersensitivity in the rat
spinal nerve ligation (SNL) model. Intrathecal injection
(i.t.) of the selective 5-HT3 receptor antagonist Y25130
(30 fmol) alone did not produce an effect on baseline
of thermal and mechanical sensitivity in sham animals
(Figure 1A and B), shown by withdrawal latencies (PWLs)
to noxious heat (Figure 1A) and withdrawal threshold
(EF50) to mechanical stimulation (Figure 1B), suggesting
an absence of tonic activation of spinal 5-HT3 receptors in
the rats without injury. However, this dose of Y25130 sig-
nificantly and reversibly attenuated SNL-induced thermal
hyperalgesia and mechanical allodynia at least for 24 h
when compared with the response in vehicle-treated rats(Figure 1A and B), indicating that spinal 5-HT3 receptors
mediate descending pain facilitation during the develop-
ment of persistent pain. To mimic the direct effect of acti-
vating the spinal 5-HT3 receptors on the behavioral pain
response, we also intrathecally injected the selective
5-HT3 receptor agonist SR57227 and measured its in-
fluence on thermal and mechanical sensitivity of the hind-
paw of the rat (Figure 1C and D). SR57227 induced
significant thermal hyperalgesia as compared to vehicle
(p < 0.05, n = 6 rats per group), in a range of doses from
10 pmol to 1 nmol (Figure 1C). The hypersensitive effect
was maximal at the dose of 10 pmol, peaking at 1–2 h,
lasting at least for 4 h. A lower dose (1 pmol) was without
effect on PWLs. Conversely, a higher dose (10 nmol) of
SR57227 produced a transient increase of thermal thresh-
olds to noxious heat. Meanwhile, intrathecal SR57227 sig-
nificantly resulted in mechanical hypersensitivity at 1–4 h
after injection, in a similar range of doses (Figure 1D). To
verify whether SR57227-induced behavioral hypersensitiv-
ity was mediated by 5-HT3 receptors, Y25130 (30 fmol), a
selective 5-HT3R receptor antagonist, was injected intra-
thecally at 30 min before SR 57227 (10 pmol). The pre-
treatment of Y25130 completely blocked the thermal
hypersensitive effect of SR 57227 at 1–4 h (Figure 1E;
p < 0.05, n = 6) and mechanical allodynia at 2 h compared
to pretreatment with vehicle (Figure 1F; p < 0.001, n = 4).
This dose-exploration study in rats indicates that activa-
tion of the spinal 5-HT3 receptors induces long-lasting
hyperalgesia and allodynia, supporting recent findings that
spinal 5-HT3 receptor activation is involved in the deve-
lopment of descending pain facilitation.
Selective activation of spinal 5-HT3 receptors induce
hyperactivity of microglia and astrocytes
What are possible mechanisms underlying spinal 5-HT3
receptor activation-induced hyperalgesia and allodynia? In
the spinal cord glial activity is critical for the induction
and maintenance of hyperalgesia after tissue and nerve in-
jury. Thus, we hypothesized that 5-HT3 receptor-induced
hyperalgesia and allodynia involved changes in the activity
of spinal glial cells. Biochemical markers for microglia
(Iba1 or CD11b) and astrocytes (GFAP) were used to
determine the location of glial expression using immuno-
histochemistry (Figure 2A) and to assess the changes in
expression using Western blotting (Figure 2B) after spinal
5-HT3 receptor activation. The microglia and astrocytes
exhibited hypertrophy with thicker processes and larger
and densely stained cell bodies in spinal dorsal horn at L5
2 h after intrathecal injection of SR 57227 (10 pmol) in
comparison with vehicle treatment (Figure 2A). Consis-
tently, a significantly enhanced expression pattern of both
GFAP and Iba1 was identified by Western blot analysis in
the lumbar spinal dorsal horn at 2 h after application of
SR 57227 (Figure 2B). However, we did not find significant
Figure 1 Attenuation of nerve injury- or intrathecal 5-HT3 receptor agonist SR57227-induced behavioral hypersensitivity by intrathecal
treatment of 5-HT3 receptor antagonist Y25130. A-B: Nerve injury-induced thermal hyperalgesia (A) and mechanical allodynia (B) at 2 weeks
after the left L5 spinal nerve ligation were significantly attenuated for 24 h after post-treatment of Y25130 (30 fmol, i.t.) compared with vehicle.
***, p < 0.001, **, p < 0.01, SNL + Y25130 vs. SNL + vehicle. n = 4–6 per group. C-D: SR57227 (10 pmol −1 nmol) induced significant decreases in
thermal paw withdrawal latencies (PWLs) (C) and mechanical EF 50s (D) after intrathecal injection compared with vehicle saline (*, p < 0.05, n = 6
rats per group). Note that SR57227 at the 10 pmol dose produced a longer thermal hyperalgesia and mechanical allodynia lasting for 4 h; at a
higher dose (10 nmol), SR57227 induced a transient hypoalgesia and at a lower dose (1 pmol) did not change thermal nociception (C). E: At 2 h
time point, SR57227-induced thermal hyperalgesia was completely blocked by pretreatment of 5-HT3 receptor antagonist Y25130 (30 fmol, i.t.)
but not saline, each of which was injected 30 min before the injection of SR57227 (10 pmol, i.t.) F: SR57227-induced mechanical hypersensitivity
was totally reversed by pretreatment of Y25130 (30 fmol, i.t.) at 2 h after injection. *, p < 0.05, ***, p < 0.001, vs. saline + saline; #, p < 0.05,
###, p < 0.001, vs. saline + SR57227; n = 4–6 per group).
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after intrathecal injection of SR 57227 (data not shown).
These results suggest that there is functional hyperactivityor reactivation of microglia and astrocytes in the spinal
dorsal horn after direct activation of local 5-HT3
receptors.
Figure 2 Selective activation of 5-HT3 A receptors induces increase of both GFAP and Iba1 expression in the spinal dorsal horn but not
in glial cells. A. Immunoreactivity of GFAP, a marker of astrocytes, and Iba1 or CD11b, markers of microglia. Upper panels are of the spinal dorsal
horn of rats at 2 h after receiving 10 pmol SR 57227 or vehicle. An increased expression of GFAP, Iba1 or CD11b was observed in an enlarged
superficial dorsal horn (lower panels) corresponding to the small rectangle area in upper panels when compared to the vehicle-treated rats. B.
Western blots at the expected molecular weights illustrate significant increases in the levels of GFAP and Iba1 in the spinal dorsal horn of rats
at 2 h after intrathecal injection of SR57227 (10 pmol) compared with rats receiving saline. Representative blots are shown above and relative
protein levels (% of naive) are shown in the bottom histograms (*, p < 0.05, **, p < 0.01, vs. saline group, n = 3 per group). C. Double immunostaining
shows that SR57227 (10 pmol, i.t.)-induced GFAP or CD11b expression in the dorsal horn astrocytes or microglial cells was not colocalized with 5-HT3A
receptor immunoreactivity. Scale bar = 25 μm.
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not glia
Since SR57227 induced astrocytic and microglial hyper-
activity, we wondered whether this compound directly
acted on glial cells to produce its effects. Although the
existence of the 5-HT3 receptor has been reported in neu-
ronal soma and terminals in the dorsal horn [20,21,25], it
is not known whether the 5-HT3 receptor is also expressed
in spinal glial cells. Therefore, we examined the distribu-
tion of the 5-HT3A receptor in the spinal cord and itspossible expression in glial cells. As shown in Figure 3A,
intense immunoreactivity of the 5-HT3A receptor was ob-
served in the superficial layers of the spinal dorsal horn. In
addition, weak to moderate expression of 5-HT3 receptors
was scattered throughout the spinal cord. Western blot
analysis showed no significant differences in the level of
5-HT3 receptor among groups of naïve rats and rats in
which SR 57227 or saline was intrathecally injected (n = 3
per group, data not shown). Double immunolabeling with
5-HT3A receptor and GFAP or CD11b showed no
Figure 3 5-HT3A receptor expression in spinal dorsal horn
neurons. A. Distribution of 5-HT3A receptor expression in the spinal
dorsal horn under low magnification. Intense expression of 5-HT3A
receptor immunoreactivity was mainly observed in the superficial layers
of the spinal dorsal horn. B. Double immunostaining showing 5-HT3A
receptor profiles also labeled with NeuN, a neuronal marker in the
dorsal horn cells (arrows), from the inset of A. C. Colocalization of
immunoreactivity of 5-HT3A receptor and fractalkine in the spinal
dorsal horn cells. Arrows indicate examples of double-labeled profiles.
Scale bar = 100 μm (A) and 25 μm (B and C).
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glia including glial soma and processes (Figure 2C). Simi-
larly, labeling for the 5-HT3 receptor was not seen in both
hyperactive astrocytic and microglial elements in the
spinal dorsal horn following administration of SR 57227
(data not shown). In contrast, 5-HT3A receptors were dis-
tributed throughout neuronal soma and many neurites in
the spinal dorsal horn, typically as small clusters asso-
ciated with the cell membrane of the neurons labeled with
NeuN (Figure 3B). Consistent with previous reports
[20,21], these data confirm that 5-HT3 receptors are pri-
marily expressed in some neuronal soma and terminals
but not glial cells in the spinal dorsal horn.
5-HT3 receptor-labeled neurons express fractalkine in the
dorsal horn
In view of the absence of 5-HT3A receptors in glial cells
of the spinal dorsal horn, we reasoned that 5-HT3
receptors-expressing neurons or terminals may mediate
SR57227-induced glial hyperactivity by releasing neuro-
active substances. The chemokine, fractalkine (CX3CL1)
has been found in sensory afferents and intrinsic spinalcord neurons [38] whereas its receptor, CX3CR1, is ex-
pressed predominantly in microglia [39-41] and may act
as a specific neuron-to-glia signal in the spinal cord [32].
Therefore, to identify the possible participation of frac-
talkine as a signaling molecule between neuron and glia
in SR 57227-induced behavioral hypersensitivity and glial
hyperactivity, we investigated the expression of fractalk-
ine in 5-HT3A receptor-labeled neurons in the spinal
dorsal horn. Immunoreactivity of fractalkine was ob-
served in numerous dorsal horn neurons (Figure 3C)
and terminals (data not shown). Double staining indi-
cated that all 5-HT3A receptor-labeled neuronal soma in
the dorsal horn strongly expressed fractalkine (Figure 3C).
Consistent with previous observations [39,40], we identi-
fied the colocalization of CX3CR1 in microglia in the
spinal dorsal horn by double labeling for CX3CR1 and
CD11b (Figure 4A). These data suggest that fractalkine
may directly mediate signaling from 5-HT3 receptor-
expressing neurons to microglia.
Up-regulated CX3CR1 and activated microglia contribute
to SR57227-induced hyperalgesia/allodynia and glial
hyperactivity
To assess the role of CX3CR1 in downstream events
subsequent to 5-HT3 receptor activation, we measured
the change of tissue CX3CR1 expression in the spinal
dorsal horn after intrathecal injection of SR57227.
Western blot analysis showed a transient up-regulation
of CX3CR1 level after application of SR 57227 (10
pmol, i.t.) compared with saline (p < 0.05, n = 3 for each
group) (Figure 4B). Furthermore, to identify whether
CX3CR1 activation mediates SR57227-induced increase
of expression of Iba1 protein, we examined the effect of
a neutralizing antibody for CX3CR1 on SR57227-
induced microglial hyperactivity. This neutralizing anti-
body (CX3CR1 Ab, 20 μg), intrathecally injected at 1d
before and concurrently with SR57227 (10 pmol), sig-
nificantly attenuated the enhancement of spinal Iba1
expression at 2 h induced by application of SR57227
(Figure 4C) (p < 0.05, n = 3). Next, we also examined
the effect of blockade of CX3CR1 on SR57227-induced
behavioral hypersensitivity. Consistent with a finding
that CX3CR1 KO mice showed an attenuation of mech-
anical and thermal hypersensitivity after nerve injury
when compared with CX3CR1 WT mice [42], the pre-
treatment with CX3CR1 Ab (20 μg, i.t.) significantly at-
tenuated the thermal hypersensitivity (Figure 4D left
panel) (p < 0.05, n = 5 for each groups) and the mechan-
ical allodynia at 2 h (Figure 4D right panel) (p < 0.001,
n = 5 for each groups) after application of SR57227. In-
jection of the antibody alone did not affect PWLs and
EF50 (Figure 4D). However, this is in contrast to the
finding reported by Staniland and colleagues that
CX3CR1 KO mice displayed only a loss of thermal
Figure 4 Attenuation of SR57227-induced upregulation of fractalkine receptor CX3CR1 in spinal microglia and behavioral hypersensitivity
to a neutralizing antibody against CX3CR1. A. CX3CR1 immunoreactivity exists in all dorsal horn microglial cells (arrows) expressing CD11b at
2 h after intrathecal SR57227 (10 pmol). Scale bar = 25 μm. B. Western blot analysis showing a significant upregulation in the levels of CX3CR1 in
the spinal dorsal horn tissue in rats at 1 and 2 h after intrathecal injection of SR57227 (10 pmol) but not vehicle saline (*, p < 0.05, vs. saline, n = 3
per group). C. SR57227-induced increases in the protein levels of Iba1 in the spinal dorsal horn tissue were significantly blocked by a neutralizing
antibody against CX3CR1 (CX3CR1 Ab, 20 μg) at 2 h after co-administration (*, p < 0.05, vs. saline + saline; #, p < 0.05, CX3CR1 Ab + SR57227 vs.
saline + SR57227; n = 3 per group). D. Thermal (left) and mechanical (right) hypersensitivity induced by SR57227 (10 pmol, i.t.) was partially
eliminated by pretreatment with a CX3CR1 neutralizing antibody (Ab) (20 μg, i.t.) 1 d before and concurrently with SR57227 at 2 h after injection
of SR 57227. *, p < 0.05, vs. saline + saline; #, p < 0.05, CX3CR1 Ab + SR57227 vs. saline + SR57227, n = 5 per group).
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intraplantar injection of zymosan [42], suggesting that
the fractalkine-CX3CR1 signaling cascade can be differ-
entially affected depending on the pathological pain
model and the stimulus modality. All of the above find-
ings implicate the fractalkine-CX3CR1 signaling cas-
cade in neuron-microglial interaction during glialhyperactivity and behavioral hypersensitivity after neur-
onal 5-HT3 receptor activation at the spinal level.
We then tested whether the effect induced by endo-
genous fractalkine release from 5-HT3 receptor-activated
neurons was mimicked by application of exogenous frac-
talkine. Intrathecal delivery of fractalkine (40 ng/10 μl),
but not vehicle, produced a significant mechanical
Figure 5 Fractalkine-induced hypersensitivity and up-regulation of IL-18 are mediated by spinal microglia. A. Fractalkine (40 ng, i.t.)
induced behavioral hyperalgesia (p<0.001, one-way ANOVA, n = 4 for each group; *, p<0.05, **, p<0.01, vs. baseline), which was significantly attenuated
by pretreatment with a neutralizing antibody against CX3CR1 (CX3CR1 Ab, 20 μg, i.t.) (#, p<0.05, ##, p<0.01 vs. saline + fractalkine). B. Fractalkine (40 ng)
increased CD11b or Iba1 expression (lower panels); lower panels are from the insets of the spinal dorsal horn (upper panels, respectively) at 1 h after
intrathecal injection when compared with vehicle treatment. Scale bar=100 μm (upper panels) and 25 μm (lower panels). C. The expression of Iba1 and
IL18 in the spinal dorsal horn was increased at 2 h after injection of fractalkine (40 ng, i.t.) when compared with saline group (*, p<0.05, n=3 per group);
such upregulation was significantly attenuated by pretreatment of CX3CR1 Ab (20 μg, i.t.) (#, p<0.05, n=3). D. IL18 in the dorsal horn was upregulated 2 h
after i.t. SR57227 (10 pmol) or fractalkine (40 ng) but not vehicle when compared with that in naïve rat (n=3-4 per group). Scale bar=100 μm. E. Increased
expression of Iba1 but not GFAP in the dorsal horn glial cells was colocalized with IL-18-IR at 2 h after fractalkine treatment (40 ng, i.t. n=3-4). There was
no coexpression of IL-18 and NeuN. The right upper panel is an enlarged area from the inset from the dorsal horn in the left upper panel. Scale bar=100
μm (the left upper panel) and 25μm (the right upper, middle and lower panels). F. IL-18 was increased in the dorsal horn at 2 h after i.t. SR57227 (10 pmol,
n=3) (*, p<0.05) compared with that with saline (i.t., n=3). CX3CR1 Ab (20 μg, i.t., n=3) prevented the effects of SR57227 on IL-18 expression (#, p<0.05).
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up to 3 h (p < 0.05 or 0.01 vs. saline + saline, n = 4 per
group) (Figure 5A) and a similar pattern of thermal
hyperalgesia peaking at 40–60 min after injection (data
not shown). In addition, both immunostaining and
Western blotting analysis showed an enhanced hyper-
activity of microglia at 1 h after the delivery of fractalk-
ine, along with increased expression of Iba1 or CD11b
(Figure 5B and C) in the spinal dorsal horn. Moreover,
the hyperalgesic effect of fractalkine or the induced en-
hancement of spinal Iba1 expression was significantly
attenuated by pretreatment with CX3CR1 Ab at 20 to
140 min (p < 0.05 vs. saline + fractalkine) (Figure 5A) or
1 h (Figure 5C) after injection, respectively. Thus, the
functional effects of blockade of CX3CR1 activation on
fractalkine-induced increase of Iba1 and behavioral hyper-
sensitivity further support our hypothesis that endogenous
fractalkine released from 5-HT3 receptor-containing neu-
rons or terminals results in microglial activation by acting
on its receptor CX3CR1 mainly expressed on microglia in
the dorsal horn.
Up-regulated IL-18 in microglia and IL-18 receptor in
astrocytes mediate microglia-astrocytic interaction during
SR57227-induced hyperalgesia and allodynia
Hyperactive microglia are known to synthesize and
secrete many glioactive substances such as proinflam-
matory cytokines involved in microglia-astrocytic inter-
action, the modulation of neuronal activity and the
enhancement of hypersensitivity to noxious input.
Thus, we further identified downstream effects of
spinal microglial activation after intrathecal administra-
tion of SR57227 or fractalkine. Although many chem-
ical mediators including proinflammatory cytokines
have been found to be involved in microglia-dependent
signaling cascades, we speculated that IL-18 may con-
tribute to the downstream effects because of its unique
expression in microglia and its receptor primarily
found in astrocytes in the spinal dorsal horn as well as
its crucial role in glial mechanisms underlying the de-
velopment and maintenance of mechanical allodynia
[43]. Thus, we determined whether the IL-18/IL-18 re-
ceptor signaling pathway in spinal microglia-astrocyte
interaction contributed to SR 57227- or fractalkine-in-
duced pain hypersensitivity. Western blot analysis dem-
onstrated that selective activation of CX3CR1 by
intrathecal fractalkine resulted in significant increase of
IL-18 expression in the spinal dorsal horn (Figure 5C)
when compared with vehicle treatment (p < 0.05, n = 3
for each group), which was also suppressed by pretreat-
ment with CX3CR1 Ab (p < 0.05, vs. saline + fractalk-
ine) (Figure 5C). Consistently, higher intensity of IL-18
immunoreactivity was visualized in the dorsal horn
cells at 2 h after intrathecal fractalkine but not vehicle,compared to that in the naïve condition (Figure 5D).
Double immunostaining further confirmed that IL-18
was predominantly expressed in microglia labeled by
Iba1 immunoreactivity in the dorsal horn (Figure 5E),
consistent with previous observations [43]. There was
little or no colocalization of IL-18 with GFAP or NeuN
(Figure 5E). Moreover, we evaluated the changes of
IL-18 during microglial hyperactivity after intrathecal
injection of SR57227. Similar to the effect of fractalk-
ine, activation of spinal 5-HT3 receptors induced
significant increase of IL-18 immunoreactive intensities
shown by immunostaining (Figure 5D) or IL-18 protein
levels measured by Western blots (Figure 5F) in the
dorsal horn. Compared to that in vehicle group,
SR57227-enhanced IL-18 expression was significantly
prevented by pretreatment with intrathecal CX3CR1 Ab
(Figure 5F) or blocked by Y25130 (p < 0.05, 136.7 ± 3.5%
in Y25130 + SR57227 vs. 187.2 ± 6.7% in saline +
SR57227). Treatment of Y25130 alone did not change
baseline expression of IL18 in spinal dorsal horn (96.7 ±
4.5%, p > 0.05, vs. vehicle group) (n = 3 for each group).
In contrast to IL18 expression in microglia, the IL-18 re-
ceptor (IL-18R) was present in GFAP labeled astrocytes
but not in microglia and neurons (Figure 6A). Thus, spinal
IL-18R expression during glial hyperactivity after intra-
thecal injection of SR57227 or fractalkine was examined.
Immunostaining showed an increase of GFAP expression
accompanied by enhanced intensity of IL-18R immunore-
activity in the dorsal horn cells after intrathecal injection
of fractalkine (40 ng) when compared to that treated
by vehicle (Figure 6C). Pretreatment with CX3CR1 Ab re-
duced fractalkine-induced increases of spinal GFAP and
IL-18R expression (Figure 6C). Quantification of this
effect was obtained with Western blotting for fractalkine-
induced upregulation of astrocytic IL-18R in the dorsal
horn, which were significantly blocked by pretreatment
with CX3CR1 Ab (Figure 6D). In order to verify whether a
hyperactivity of spinal astrocytes was downstream of
spinal microglial activation, we also analyzed the effects of
functional blockade of these cytokine receptors primarily
expressed on microglia or astrocytes on the enhanced
expression of GFAP induced by SR57227 and fractalkine.
We found that SR57227-induced elevation of GFAP ex-
pression was significantly attenuated after blocking the
fractalkine-mediated signal transduction cascade with
anti-CX3CR1 antibody (p < 0.05, Figure 6B). Also, fractal-
kine-induced GFAP increase was significantly attenuated
after functional blockades of either CX3CR1 expression in
microglia (Figure 6D) or IL-18 receptors expressing in as-
trocytes (Figure 6E). These data suggest an increase in the
functional interaction between microglial and astrocytic
hyperactivity via a key IL-18/IL-18R signaling pathway
during the development of hyperalgesia induced by 5-HT3
receptor activation and exogenous fractalkine.
Figure 6 Astrocytic hyperactivity and up-regulation of IL-18R in spinal astrocytes induced by SR57227 and fractalkine. A. IL-18R expression
in the dorsal horn (a’ and b’) and its colocalization (d’) with GFAP (c’) but not with CD11b (e’) or NeuN (f’), suggesting that IL-18R is only expressed
in spinal astrocytes of normal rats. Scale bar=100 μm (a’) and 25 μm (b’-f’). B. SR57227 (10 pmol, i.t.) induced a significant enhancement of GFAP
expression in the dorsal horn at 1 h (*, p<0.05, vs. vehicle, n=3 per group), which was suppressed by pretreatment with CX3CR1 Ab (20 μg, n=3)
(#, p<0.05 vs. saline + SR57227). C. Fractalkine (40 ng, i.t., n=4)-induced increases of both GFAP (upper panels) and IL-18R (lower panels) expression
were significantly attenuated by pretreatment with CX3CR1 Ab (Ab, 20 μg, i.t., n=3) at 1 h after injection of fractalkine. Scale bar=25 μm. D The
levels of IL-18R and GFAP are significantly increased in the dorsal horn at 1 h after fractalkine treatment (40 ng, i.t., n=3) compared with that
treated by saline (*, p<0.05, or **, p<0.01, n=3 for each group); such upregulation for GFAP was significantly reduced by pretreatment with
CX3CR1 Ab (20 μg, #, p<0.05, vs. saline + Fractalkine, n=3 per group); fractalkine-induced increase of IL-18R expression was also attenuated by
CX3CR1 Ab (#, p<0.05, n=3) but did not return to basal expression found in the saline + saline treated group (*, p<0.05). E. Fractalkine-induced
increase of GFAP expression in the dorsal horn was partially suppressed by pretreatment with IL-18 Ab (20 μg, i.t.) (*, p<0.05, vs. saline + saline;
#, p<0.05, vs. saline + fractalkine; n=3 for each group). These data suggest that SR57227 or fractalkine-induced up-regulation of GFAP is mediated
by activation of CX3CR1 expression in spinal microglia and of IL-18R in astrocytes.
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SR57227-induced pain behavior through
phosphorylation of neuronal GluNRs (NMDARs)
Hyperactivated microglia and astrocytes in the spinal dor-
sal horn and the brain stem trigeminal transition zone are
known to secrete prototypic inflammatory cytokines suchas IL-1β and are involved in central sensitization and be-
havioral pain hypersensitivity [44-47]. To test whether
SR57227-induced hyperalgesia and allodynia involve
IL-1β, we examined the effect of 5-HT3 receptor activa-
tion on spinal IL-1β expression and found that spinal de-
livery of SR57227 (10 pmol) but not vehicle induced a
Figure 7 Upregulation of IL-1β in the dorsal horn astrocytes and its involvement in pain behavior after intrathecal injection of
SR57227. A. SR 57227 (10 pmol, i.t., n = 4) or fractalkine (40 ng, i.t., n = 4) produced an increased expression of IL-1β (lower panels) in the area from
the inset in the spinal dorsal horn (upper panels) compared to saline at 2 h or 1 h after injection, respectively. Scale bar = 100 μm (upper panel) and
25 μm (lower panel). B. Western blot analysis showed increases in the levels of IL-1β in the spinal dorsal horn tissue of rats treated with SR 57227
(10 ng, i.t., *, p < 0.05 at 1 and 4 h, **, p < 0.01 at 2 h, vs. saline, n = 3 per group). C. Dense colocalization of IL-1β and GFAP (lower panels) but not
CD11b in glial cells (upper panels) in the spinal dorsal horn in rats treated with SR 57227 (10 pmol, i.t., n = 3) at 2 h after injection, suggesting that
IL-1β was predominantly expressed in spinal astrocytes. Scale bar = 25 μm. D. SR 57227 (10 pmol, i.t.)-induced mechanical hypersensitivity was
attenuated at 2 h after the injection by the antagonist of IL-1 receptor, IL1-ra (10 μg, i.t.) 1d before and concurrently with SR 57227 (***, p < 0.001,
saline + SR 57227 vs. saline + saline; # p < 0.05, IL1-ra + SR 57227 vs. saline + SR 57227) (n = 5 per group). E. SR 57227 (10 ng, i.t.) significantly induced
up-regulation of IL-1β at 2 h after injection (*, p < 0.05, vs. saline + saline), which was attenuated by pretreatment with CX3CR1 Ab (20 μg, i.t.) (#, p < 0.05,
vs. saline + SR57227) (n = 3 per group).
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cells (Figure 7A) or in the dorsal horn tissues (Figure 7B,
p < 0.05 at 1 and 4 h, p < 0.01 at 2 h, vs. saline groups,
n = 3 per group). A similar effect of exogenous fractalkine
(40 ng) on spinal IL-1β expression was observed
(Figure 7A). Next, we showed with double labeling that
IL-1β was mainly expressed in hyperactive astrocytes
immunoreactive for GFAP but rarely in microglia immu-
noreactive for CD11b in the spinal dorsal horn afterinjection of SR57227 (Figure 7C). We then examined
whether IL-1β contributed to behavioral hypersensitivity
induced by SR57227. IL-1ra (100 μg/10 μl), an IL-1 recep-
tor antagonist, was injected intrathecally 1d before and
concurrently with SR 57227. The SR57227-induced mech-
anical allodynia was significantly attenuated by pretreat-
ment with IL-1ra at 2 h measured (Figure 7D). Thermal
hyperalgesia induced by spinal 5-HT3 receptor activation
was also reversed by intrathecal IL-1ra for 4 h (data not
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group). To demonstrate a one-way intercellular communi-
cation involving up-regulation of IL-1β evoked by spinal
microglial and astrocytic activation, we blocked microglial
receptor CX3CR1 or astrocytic IL-18 receptors and eva-
luated their effects on the increased expression of spinal
IL-1β after intrathecal SR57227 or fractalkine. Western
blotting showed that SR57227 induced enhancement of
IL-1β expression in the dorsal horn tissue at 2 h after
injection, when compared with vehicle treatment, and was
significantly reduced with pretreatment with the CX3CR1
neutralizing antibody (p < 0.05, n = 3 for each group,
Figure 7E). Meanwhile, fractalkine-induced increase of
IL-1β level in the spinal dorsal horn was partially blocked
by pretreatment with IL-18R Ab (p < 0.05, 128.2 ± 9.8% in
IL-18R Ab + Fractalkine vs. 223.7 ± 7.6% in saline + Frac-
talkine, n = 3 for each group). Treatment of IL-18R Ab
alone did not effect on basal IL-1β expression in spinal
dorsal horn (96.7 ± 4.5%, p > 0.05, vs. vehicle group, n = 3
for each group). Thus, these data confirm that the
enhanced expression of IL-1β in spinal astrocytes was in-
duced by hyperactive microglia and activated IL-18 recep-
tors in astrocytes in the dorsal horn.
It has been shown that glutamate receptor subunit GluN
(NMDA) receptors (GluNRs) are widely expressed in rat
dorsal horn neurons and are upregulated and phosphory-
lated in the dorsal horn by locally released proinflammatory
cytokines after injury, contributing to pain hypersensitivity
[35,47-49]. To study mechanism of glial-neuronal interac-
tions, we examined whether IL-1RI, the receptor for IL-1β,
was distributed in dorsal horn neurons containing GluNRs.
Double labeling showed that IL1RI colocalized with the
GluN1R subunit, a principal component of GluNRs in rat
dorsal horn neurons (Figure 8A). To test whether spinal
5-HT3 receptor activation also induced GluNRs activation,
the phosphorylation levels of GluN1R (pGluN1R), a func-
tional marker of neuronal excitability in the CNS, were
measured in spinal dorsal horn tissues. As shown in
Figure 8B, the expression of pGluN1R ser896 in the spinal
dorsal horn was robustly increased by threefold at 2 h after
intrathecal injection of SR57227 (10 pmol) when compared
with sham group (p < 0.001, n = 3 each group). Moreover,
SR57227-induced increase of the pGluN1R expression was
significantly attenuated by pretreatment with the neutraliz-
ing antibodies for CX3CR1, IL-18R or IL1RI (p < 0.001,
Figure 8B), Meanwhile, these pretreatments alone had no
effect on baseline expression of pGluN1 in the spinal dorsal
horn (Figure 8B). These findings confirm that the increase
of pGluN1 observed above was mediated mainly by
fractalkine to CX3CR1, IL-18 to IL-18R and IL-1β to IL1RI
signaling pathways, suggesting that spinal 5-HT3 receptor
mediated hyperalgesia and allodynia in rat primarily
depends on a neuron-microglia-astrocyte-neuronal signal
cascade.Descending 5-HT and spinal 5-HT3 receptors involved in
dorsal horn glial hyperactivity underlying descending
pain facilitation and inflammatory pain
Recently, it has been well recognized that microglial and
astrocytic hyperactivity in the dorsal horn play a critical
role in the development of inflammatory pain after
tissue injury [27-30 for reviews]. We previously found
that the RVM-spinal 5-HT system is also implicated in
descending pain facilitation involving in central mecha-
nisms of persistent pain after peripheral inflammation
[16] or nerve injury [25,37]. To confirm the effect of the
descending 5-HT system on glial hyperactivity to peri-
pheral inflammation in rats with persistent pain, we
examined changes of spinal glial markers in a model of
inflammatory pain induced by intraplantar injection of
CFA from 3 d after molecular depletion of intra-RVM
5-HT system manipulated by local gene transfer of
Tph-2 shRNA as shown previously [16]. In the control
shRNA-treated rats, Western blot showed that there
were robust increases of CD11b and GFAP expression in
the spinal dorsal horn at 1 d after unilateral intraplantar
CFA injection, compared with that in the saline group
(p < 0.01, n = 3 for each group, Figure 8C). However,
Tph-2 shRNA-treated animals exhibited significant at-
tenuation of CD11b and GFAP expression after CFA in-
jection as compared to rats treated with control shRNA
(p < 0.05, n = 3 for each group, Figure 8C), suggesting
that active 5-HT-dependent descending pain facilitation
contributes to the maintenance of spinal glial hyperac-
tivity underlying the development of inflammatory pain
after injury. Thus, the spinal glial changes appear to be
involved in descending facilitation underlying the main-
tenance of persistent pain via descending 5-HT release
and spinal 5-HT3 receptor activation after injury.
Discussion
Our findings demonstrate that a neuron-glia-cytokine-
neuronal signaling cascade is involved in the mechanisms
underlying spinal 5-HT3 receptor-mediated hyperalgesia.
The development of persistent pain after inflammation
and nerve injury appears to be dependent, in part, upon
5-HT pathways originating from the rostral ventromedial
medulla leading to activation of 5-HT3 receptors at the
spinal level [5,16,19,22,24,25,37]. Consistent with these
views and a recent study [50], our data showed that bloc-
kade of spinal 5-HT3 receptor function by intrathecal
Y25130, a selective 5-HT3 receptor antagonist, attenuated
mechanical and thermal hypersensitivity following L5 SNL
in rats. Interestingly, some studies reported that intra-
thecal injection of 5-HT3 receptor antagonists such as
CGP35348 [51] or ondansetron [52] had no preventive ef-
fects on mechanical allodynia and/or thermal hyperalgesia
in a rat with L5/6 SNL, which conflicts with the study with
the same drug ondansetron in the same SNL model [50]
Figure 8 Upregulation of NMDAR phosphorylation in dorsal horn after activation of 5-HT3Rs and descending 5-HT-dependent spinal
glial hyperactivity after inflammation. A. IL-1RI was colocalized with GluN1R in dorsal horn neurons. Enlarged regions (the three right panels)
correspond to the rectangle area in the left panel. Scale bar=50 μm (the left panel) and 25 μm (the three right panels). B. p-GluN1R was increased in
the dorsal horn at 2 h after i.t. SR57227 (10 pmol, i.t.; ***, p<0.001, n=3), which was significantly attenuated by pretreatment with CX3CR1 Ab (20 μg, i.t.,
n=3), IL18R Ab (20 μg, i.t., n=3) or IL-1ra (10 μg, i.t., n=3) (####, p<0.001 vs. saline + SR 57227; but *, p<0.05 or **, p<0.01, vs. saline + saline), respectively.
C. CD11b and GFAP were increased in the dorsal horn after hindpaw injection of CFA in rats treated with control or Tph-2 shRNA in the RVM (*, <0.05
or **, p<0.01, vs. saline group), however, intra-RVM Tph-2 shRNA reduced CFA-produced increases of spinal CD11b and GFAP expression, in comparison
with control Tph-2 shRNA (#, p<0.05) (n=3 for each group). Treatment with Tph-2 shRNA alone in the RVM didn’t affect basal expression of spinal
CD11b and GFAP when compared to control shRNA. D. Proposed signal pathways involved in pain hypersensitivity after 5-HT3 receptor activation
in the spinal cord. Some excitatory spinal neurons and primary afferent terminals expressing 5-HT3 receptors are activated by the 5-HT3R agonist.
Fractalkine is released from the 5-HT3R-containing neurons or sensory afferents, and then acts on its receptor, CX3CR1 that is mainly expressed in
microglia. Hyperactivity of microglia consequently evokes astrocytes through an IL18/IL18R signaling and induces astrocytic IL-1β release. The released
IL-1β contributes to neuronal hyperexcitability and behavioral hypersensitivity via IL-1β receptors (IL-1RI) and enhancement of pGluN1R on spinal dorsal
horn neurons.
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expected plastic changes of both 5-HT immunoreactive
intensity and 5-HT3 receptor innervation in the lumbar
spinal dorsal horn at 14 d after L5/L6 SNL in the study re-
ported by Peters and colleagues [52]. In contrast, we
found a robust increase of tissue Tph-2 level in the RVM
[16] at 14 d and a progressive enhancement of tissue
5-HT3 receptor expression in the spinal dorsal horn from
1 d to 28 d after nerve injury when compared with that in
the sham group (unpublished observations). We suspect
that the discrepancies between our positive findings and
those reported by Peters et al. [52] could be attributed to
the utilization of different neuropathic pain models and
different 5-HT3 receptor antagonists as well as the ab-
sence of more quantitative measures used for the 5-HT3
receptor expression and fewer time points measured after
injury in their study. In the present study, our data indi-
cate that the effective dose of intrathecal Y25130 for at-
tenuation of behavioral hypersensitivity following SNL did
not alter thermal and mechanical thresholds in the sham
animals at 14 d after surgery. Thus, we propose that in-
creased descending 5-HT drive and spinal 5-HT3 receptor
expression after tissue and nerve injury contribute to the
maintenance of central sensitization, including glial hyper-
activity and neuronal hyperexcitability at the spinal level
underlying the development of persistent pain.
We have determined that a number of chemical me-
diators contribute to the spinal 5-HT3 receptor-induced
novel spinal signaling cascade that includes the chemo-
kine, fractalkine released from 5-HT3 receptor-containing
neurons, cytokine IL-18 released from microglia, IL-1β re-
leased mainly from astrocytes, enhanced phosphorylation
of spinal NMDA receptors, and ultimately behavioral
hyperalgesia. Moreover, the mechanisms by which these
events are sequentially activated through multiple sig-
naling cascades to link neuron-microglia-astrocyte-neu-
ronal interactions (Figure 8D) is unexpected and novel,
and highlights how cellular circuitry and molecular sig-
naling interact in the spinal dorsal horn response to
5-HT3 receptor activation. The findings indicate that
spinal hyperexcitability or central sensitization underlying
the development of hyperalgesia not only depends on the
initiation of nociceptive input from primary afferent neu-
rons after tissue and nerve injury [35-37], but also requires
the maintenance of descending facilitation from the RVM
5-HT-spinal 5-HT3 receptor systems [25,37]. Our study
supports the growing evidence that spinal 5-HT3 recep-
tors play a crucial role in the cellular and molecular
mechanisms of the development and maintenance of per-
sistent pain states.
Our results demonstrate that there are at least three
active signaling cascades, including fractalkine and its re-
ceptor, CX3CR1, for mediating spinal neuron-to-microglia
signaling; IL-18 and its receptor for microglia-to astrocytesignaling; and IL-1β and its receptor for astrocyte-to-
neuron signaling, as important components involved in
the functional intercellular transduction in the dorsal horn
after 5-HT3 receptor activation. These findings do not rule
out the role of other chemical mediators released from the
same neurons, or different subpopulations of neurons
(excitatory or inhibitory neurons) or glial cells in the regu-
lation of spinal nociceptive processes. It has been reported
that some central terminals of primary afferent neurons
express 5-HT3 receptors [20,21]. In a recent study, we also
showed that 5-HT3 receptors in the central terminals of
primary afferent neurons are involved in enhanced pri-
mary nociceptive afferent activity and excitatory signaling
input by increasing TRPV1 function during the main-
tenance of neuropathic pain [25]. Intrathecal injection
of 5-HT3 receptor agonists may excite these central ter-
minals to release fractalkine, glutamate and ATP, and
directly activate glial cells and even directly enhance
NMDA receptor function in dorsal horn neurons.
Although these findings suggest other signaling
cascades, the converging data in the present study sug-
gest that spinal neuron-glia-neuronal interaction may
be particularly important in the 5-HT3 receptor-
mediated central sensitization associated with intra-
RVM 5-HT-dependent descending pain facilitation.
Thus, up-regulation of 5-HT3 receptor expression in the
spinal dorsal horn, following enhanced descending
5-HT drive after nerve injury, may play an important
role in glial hyperactivity involved in the maintenance of
persistent pain.
Although spinal glial hyperactivity has been reported in
acute and persistent pain models [26,29,30,53,54], few
studies have investigated the involvement of spinal 5-HT3
receptors in spinal glial hyperactivity. In the present study,
intrathecal injection of the selective activation of spinal
5-HT3 receptors by intrathecal injection of the receptor
agonist induced significant up-regulation of GFAP and
Iba1. Although Western blot analysis did not show up-
regulation of CD11b in the dorsal horn after single i.t. in-
jection of SR57227, immunostaining for CD11b exhibited
hypertrophic status of spinal microglia after SR57227,
similar to Iba1 labeling. Interestingly, up-regulation of
CD11b expression in spinal dorsal horn tissue was ob-
served at 1d after hindpaw inflammation but not 2 h after
intrathecal injection of SR57227, suggesting that increase
of CD11b expression may require longer-lasting excitatory
or nociceptive input on microglia. Molecular depletion of
the descending 5-HT system significantly attenuated per-
ipheral inflammation-produced glial hyperactivity in the
spinal dorsal horn. These data provide the first evidence
that either exogenous or endogenous activation of the
5-HT3 receptor results in spinal glial hyperactivity. More-
over, we were interested in the mechanisms by which
quiescent spinal glia alter their function in response to
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strated special expression patterns for chemokines, cyto-
kines and their receptors in spinal cord cells. For example,
fractalkine exists in spinal neurons [39,40] and its receptor
CX3CR1 is selectively expressed in microglia [40,55].
IL-18 and its receptor are present in spinal microglia and
astrocytes, respectively [43]. Consistent with our previous
study on the RVM [34,56], we found that IL-1β is mainly
expressed in astrocytes but not microglia in the spinal
dorsal horn. Its receptor IL-1RI is present in dorsal horn
neurons expressing GluNRs. These proteins have been
demonstrated to play a role in spinal nociceptive modula-
tion and the development of persistent pain after injury
[26,27,29,30]. However, previous studies have not shown a
relationship between these proteins and 5-HT3 receptor
activation in the spinal cord. In addition, extending our re-
cent findings [16,35,56], we showed the colocalization of
IL-1RI with the GluNR subunit GluN1R in dorsal horn
neurons and with IL-1RI-mediated facilitation of GluN1R
phosphorylation after 5-HT3 receptor activation. Thus,
the IL-1β-mediated amplified signaling from spinal astro-
cytes further enhances neuronal excitability through sig-
naling coupling with GluNRs in the spinal cord, which
plays an important role in neuronal hypersensitivity. Our
findings also suggest that activation of spinal 5-HT3 recep-
tor is sufficient to induce glial hyperactivity and cytokine
release which are necessary for neuronal and behavioral
hypersensitivity after 5-HT3 receptor activation. The acti-
vated glia-mediated positive signaling amplification then
sensitizes spinal nociceptive neurons, leading to further
neuronal activation and behavioral hyperalgesia. These
findings offer new insights into the cellular and molecular
mechanisms in the spinal level responsible for descending
pain facilitation during the development of persistent pain
after tissue and nerve injury.
In the present study, we directly activated the spinal
5-HT3 receptor to mimic 5-HT release through descen-
ding pain facilitation pathways [16]. We found that
intrathecal injection of 10 pmol of the 5-HT3 receptor
agonist SR 57227 produced thermal and mechanical
hypersensitivity that lasted for 4 hours. This observation
provides direct evidence that the spinal 5-HT3 receptor
plays a role in pain facilitation. Activation of 5-HT3 re-
ceptors in the spinal cord by 5-HT is mediated by the
descending excitatory drive from the RVM to the spinal
cord [5,24,37]. Consistent with studies with another
5-HT3 receptor agonist 2-Me-5H [57,58], we found that
intrathecal injection of higher doses of SR 57227
(10 nmol) induced transient analgesia. The different
doses used in our experiments may reflect different
mechanisms that depend on specific cellular circuits or
the particular proteins involved. It has been shown that
5-HT3 receptors are predominantly localized in termi-
nals of excitatory axons in the rat superficial dorsal hornand some of these originate from dorsal horn neurons
[20,21,59,60]. Although cell bodies expressing these
receptors in the dorsal horn are further identified as ex-
citatory neurons [59,61], some 5-HT3 receptor-labeled
neurons in rat dorsal horn express glutamate decarbo-
xylase (GAD), a marker for GABAnergic neurons [21].
Recent studies have demonstrated in the mouse that
some dorsal horn neurons sensitive to 5-HT3 receptor
agonists were GAD positive [62] and that some 5-HT3
receptor mRNA-containing dorsal horn neurons were
GAD positive [63]. Thus, 5-HT3 receptors appear to be
expressed in both excitatory and inhibitory intrinsic neu-
rons and terminals in the spinal dorsal horn. Synaptic
plasticity of 5-HT3 receptor expression and function in
the spinal dorsal horn neurons and the terminals of pri-
mary afferent fibers during the development of per-
sistent pain will require further study.
Conclusions
Our findings demonstrate that activation of neuronal
5-HT3 receptors in the dorsal horn evokes a novel spinal
signaling cascade including the chemokine, fractalkine re-
leased from 5-HT3 receptor-containing neurons, cytokine
IL-18 released from microglia, IL-1β released mainly from
astrocytes, and enhanced phosphorylation of NMDA
receptors in spinal neurons. This neuronal-glial-cyto-
kine-neuronal signaling cascade may be involved in the
mechanisms underlying spinal 5-HT3 receptor-mediated
5-HT-dependent descending facilitation and behavioral
hyperalgesia after tissue and nerve injury. These results
further support the growing evidence that spinal 5-HT3
receptors play a crucial role in the cellular and molecular




Adult male Sprague Dawley rats weighing 200–300 g
(Harlan, Indianapolis, IN) were used in all experiments.
Rats were on a 12 h light/dark cycle and received food
and water ad libitum. The experiments were approved
by the Institutional Animal Care and Use Committee of
the University of Maryland Dental School.
Intrathecal injection
A lumber puncture procedure was adapted according to
Hylden and Wilcox [64]. Briefly, rats were anesthetized
with 2–3% isoflurane in a gas mixture of 30% O2 ba-
lanced with nitrogen and placed in a prone position on a
styrofoam board with the forelimbs extended rostrally
and the hind limbs hanging off the board. A portion of
the caudal half of the rat’s back was shaved and scrubbed
with providone-iodine solution. A disposable 25-gauge
1-inch needle connected to a 25-μl Luer tip Hamilton
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between the L4-L5 vertebra and the needle was allowed
to penetrate the dura. A quick flick of the tail or a limb
indicated entrance into the intrathecal space. Rats awoke
within minutes upon the completion of intrathecal injec-
tion and termination of anesthesia.
Intra-RVM microinjection and gene transfer
For intra-RVM microinjection, under anesthesia with 3%
isoflurane rats were placed in a Kopf stereotaxic instru-
ment (Kopf Instruments). A midline incision was made
after infiltration of lidocaine (2%) into the skin. A mid-
line opening was made in the skull with a dental drill to
insert a microinjection needle into the target site. The
RVM is termed for collective structures that consist of
the midline nucleus raphe magnus (NRM) and the adja-
cent gigantocellular reticular nucleus α part (NGCα).
The coordinates for the NRM were as follows: 10.5 mm
caudal to bregma, midline, and 9.0 mm ventral to the
surface of the cerebellum [65]. To avoid penetration of
the transverse sinus, the incisor bar was set at 4.7 mm
below the horizontal plane passing through the inter-
aural line. Animals were subsequently maintained at 1%
halothane. For gene transfer, as previously described
(Wei et al., [16]), microinjections of the plasmids were
performed by delivering Suresilencing™ shRNA plasmid
(TCAACATGCTCCATATTGAAT, 0.5 μg/0.5 μl; Super-
Array, Frederick, MD, USA) slowly over a 10 min period
using a 0.5 μl Hamilton syringe with a 32 gauge needle.
The control group underwent identical procedures with
injection of the same volume of scrambled shRNA
plasmid (ggaatctcattcgatgcatac). Focal electroporation
around the RVM area was delivered by seven square
wave electric pulses (50 ms, 40 V, 1 Hz; model 2100;
A-M Systems, Carlsborg, WA, USA). The wound was
closed and the wound margins were covered with a local
anesthetic ointment (Nupercainal; Rugby Laboratories),
The animals returned to their cages after they recovered
from anesthesia.
Pain models and behavioral testing
To establish a persistent pain model with L5 spinal nerve
ligation (L5 SNL), rats were anesthetized with 2–3% iso-
flurane in a gas mixture of 30% O2 balanced with nitro-
gen, the left L5 spinal nerve was exposed and tightly
ligated with 4–0 soft silk thread. Sham surgery was used
as a control. To examine whether there were effects of
descending 5-HT depletion on spinal glial hyperactivity
induced by peripheral inflammation, complete Freund’s
adjuvant (CFA, 50 μl, 25 μg Mycobacterium tuberculosis)
was injected subcutaneously into the plantar surface of
the left hindpaw at 3 d following gene transfer.
Animals were placed in clear plastic chambers on an
elevated table and allowed to acclimate forapproximately 30 min. Nociceptive responses to thermal
and mechanical stimuli were measured. Thermal hyper-
algesia was assessed by measuring the latency of paw
withdrawal in response to a radiant heat source. A radi-
ant heat stimulus was applied from underneath the glass
floor with a high-intensity projector lamp bulb (8 V,
50 W; Osram, Berlin, Germany). The heat stimulus was
focused on the plantar surface of each hindpaw, and the
paw withdrawal latency (PWL) was determined by an
electronic clock circuit. The bulb voltage was adjusted to
derive a baseline withdrawal latency (10–12 s) in naive
animals. A 20-s cutoff was used to prevent tissue da-
mage. The PWL was tested for three trials with 5-min
intervals between each trial. The average of the three
trials was then determined. The mechanical sensitivity
was measured with a series of calibrated von Frey fila-
ments before and after gene transfer and tissue or nerve
injury. An EF50 value was defined as the von Frey fila-
ment force (g) that produced a 50% frequency of the
paw withdrawal responses and was used as a measure of
mechanical sensitivity. Body weight and hindpaw diame-
ters were determined before and after gene transfer as
well as at 1 and 3 d after inflammation. All behavioral
tests were conducted under blind conditions.
Intra-RVM electrical stimulation
Rats were anesthetized with 1.5% isoflurane and mounted
in a stereotaxic apparatus. The stimulation site in the
RVM was located stereotaxically as described above. A
concentric bipolar stimulating electrode was introduced
into the RVM. Trains (2 min on and 30 s off) of stimuli of
0.5 ms square wave pulse were applied with low (10 μA)
or high (100 μA) intensity at 10 Hz for 15 min. The sham
group received an electrode placement without stimula-
tion. At 30 min after stimulation, sham and treated rats
were anesthetized with 2% halothane and decapitated. The
spinal dorsal horn tissues at L4-5 were removed for
Western blot to examine the expression of CD11b and
GFAP.
Immunohistochemistry
1 h, 2 h and 4 h after intrathecal injection of drugs, rats
were deeply anesthetized with pentobarbital sodium
(100 mg/kg, i.p.) and transcardially perfused with 200 ml
normal saline followed by 500 ml 0.1 M phosphate buffer
containing 4% paraformaldehyde (pH = 7.4). The lumber
spinal cord was removed, post fixed, and transferred to
20% sucrose overnight. Transverse sections (free-floating,
20 to 40-μm) were cut with a cryostat. The free-floating
sections were incubated with relevant antibodies with 1%
normal goat sera and 0.3% Triton x-100 overnight at 4°C.
After washes in PBS, the sections were incubated with
relevant IgGs conjugated to Cy3 or Cy2 (1:500; Jackson
ImmunoResearch, West Grove, PA) for 4 h at room
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nofluorescent staining for IL-18 and NeuN, GFAP or
Iba1, the tyramide signal amplification (PerkinElmer Life
Sciences, Boston, MA) fluorescence procedures [66] were
used to detect staining for goat anti-IL-18 polyclonal anti-
body (1:10000; R & D Systems). Following washes, the
stained sections were mounted on gelatin-coated slides
and coverslipped with Vectashield (Vector Laboratories).
Slides were examined with a Nikon fluorescence micro-
scope and images were captured with a CCD Spot camera.
A Bio-Rad laser scanning confocal microscope was also
used for higher magnification and colocalization.
Western blot
Rats were sacrificed 1 h, 2 h and 4 h after intrathecal
injection of drugs. The L5-6 spinal cord was rapidly re-
moved and the dorsal half was separated and frozen on
dry ice. The tissues were homogenized in solubilization
buffer (50 mM Tris HCl, pH 8.0, 150 mM NaCl, 1 mM
EDTA, 1% NP-40, 0.5% deoxycholic acid, 0.1% SDS,
1 mM Na3VO4, 1 U/ml aprotinin, 20 μg/ml leupetin,
20 μg/ml pepstatin A). The homogenate was centri-
fuged at 14,000 rpm for 10 min at 4°C. The supernatant
was removed. The protein concentration was deter-
mined using a detergent-compatible protein assay with
a bovine serum albumin standard. Each sample con-
tains proteins from one animal. Protein samples (35 μg)
were separated on 7.5% SDS-PAGE and blotted on a
nitrocellulose membrane (GE Healthcare, Piscataway,
NJ). The blots were blocked with 5% milk in Tris-
buffered saline (TBS) for 30 min and then incubated
with respective antibodies overnight at 4°C. The mem-
brane was washed with TBS and incubated with anti-
goat/mouse/rabbit IgG (1:1000; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) for 1.5 h at room temperature.
The immunoreactivity was detected using enhanced
chemiluminescence (ECL; GE Healthcare). Some blots
were further stripped in a stripping buffer (Thermo Sci-
entific) for 30 min at 50°C. The loading and blotting of
equal amount of protein were verified by reprobing the
membrane with anti-β-actin antiserum (Sigma). Spe-
cific expression band for the targeted proteins was
identified with the marker bands for the expected mo-
lecular weight (KDa).
Data analysis
Data were presented as means ± SEM, and analyzed
using one- or two.-way ANOVA. The significant dif-
ferences between the groups were determined by a
post-hoc test. P < 0.05 is considered significant for all
cases. For Western blot analysis, the ECL-exposed films
were digitized and immunoreactive bands were quanti-
fied by U-SCAN-IT gel (version 4.3; Silk Scientific,
Orem, UT). The relative protein levels were obtainedby comparing the respective specific band to the β-
actin control from the same membrane. The deduced
ratios were further normalized to that of the naive rats
on the same membrane and illustrated as the percent-
age of the naive controls. Raw data (ratios of the re-
spective band over β-actin) were used for statistical
comparisons.Drugs and antibodies
The following drugs were used for intrathecal injection:
5-HT3 receptor agonist SR-57227 hydrochloride (TOCRIS,
Ellisvlle, MO), 5-HT3 receptor antagonist Y-25130 (TOC
RIS, Ellisvlle, MO), fractalkine (aa 22–100, R & D
Systems), neutralizing antibody against rat CX3CR1
(CX3CR1 Ab, Torrey Pines Biolabs, Houston, TX) and
IL-1β receptor (IL-1ra, Amgen, Thousand Oaks, CA),
anti-IL-18 receptor (IL-18R Ab, R & D Systems), recom-
binant rat IL-18 (R&D systems) and IL-1β (PeproTech).
The following antibodies were used for western blot and
immunohistochemistry: The polyclonal primary anti-
bodies were used in the following dilutions: anti-5-HT3
receptor (1:500, Calbiochem, Gibbstown, NJ), anti-glial fi-
brillary acidic proteins (GFAP,1:10000, Millipore, Bedford,
MA; or 1:1000, Chemicon, Temecula, CA), anti-S100β
(1:1000, Millipore, Bedford, MA), anti-Iba1 (1:1000; Wako,
Osaka, Japan), anti-fractalkine (1:1000) (Novus Biological,
Littleton, CO), anti-CX3CR1 (1:1000, Torrey Pines
Biolabs, Houston, TX), anti-IL-18 (1:400, R & D Systems),
anti-IL-18R (1:500, R & D Systems), anti-IL-1β (1:500,
Endogen, Rockford, IL), anti-IL-1R (1:500, Santa Cruz Bio-
technology), and anti-p-GluN1 (or NR1) ser896 (1:1000,
Millipore, Bedford, MA). The monoclonal primary anti-
bodies were used in the following dilutions: anti-CD11b
(clone OX-42, 1:1000, Serotec, Raleigh, NC), anti-NeuN,
(1:1000, Millipore, Bedford, MA; or 1:2000, Chemicon),
anti-GluN1 (1:1000, Millipore) and anti-β-actin (Sigma-
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